In after-hours trading on Monday, Lipocine Inc. (NASDAQ: LPCN) rose 10.60% to $0.48 on no relevant news. LPCN stock lost -4.62% to finish the trading session at $0.43 fluctuating between $0.4339 and $0.4774.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
How has LPCN been recent?
It was recently announced that Lipocine (LPCN) is planning to treat disorders of the central nervous system. LPCN announced a new strategic direction, which involves developing new CNS treatments using its Lip’ral technology.
- Endogenous neuroactive steroids are LPCN’s initial focus, where it can leverage its platform to develop highly differentiated oral therapeutics that are applicable to a wide range of CNS conditions.
- They have broad applicability in treating a wide variety of CNS conditions.
- By implementing these changes, LPCN will be able to focus on a small number of candidates in active development and manage its resources more efficiently.
- The company continues to hold its non-core candidates in high regard and believes that a partnership will be the best way to advance these assets.
- It will allow LPCN to diversify its risk and create opportunities for nondilutive financing.
CNS-focused strategic direction:
Endogenous neuroactive steroids (NAS), which are shown to significantly impact central nervous system function through allosteric modulation of the GABAA receptor, are Lipocine’s top priority.
- Due to their potential to treat multiple neuropsychiatric conditions including depression, movement disorders, epilepsy, anxiety, and neurodegenerative diseases, NAS has received considerable attention as a novel class of drugs.
- A key advantage of Lipocine’s technology is that it can be used to deliver endogenous GABAA receptor modulators orally, which are traditionally difficult to deliver due to poor water solubility.
- Recently, Lippocine announced that the US Food and Drug Administration (“FDA”) agreed with its proposal to establish LPCN 1154’s efficacy by filing an NDA with a pivotal pharmacokinetic (“PK”) bridge to an approved IV infusion of brexanolone.
- In the first quarter of 2023, results are expected from the pilot PK bridge study (a prerequisite to the pivotal NDA study).
Non-core assets to be monetized
A portfolio of clinical-stage candidates has been developed by Lipcine, including LPCN 1144 for treating non-cirrhotic NASH, LPCN 1148 for treating decompensated liver cirrhosis, LPCN 1107 for preventing preterm births, and LPCN 1111 for treating TRT once a day.
This strategy aims to diversify risks and potentially create non-dilutive financing opportunities by advancing these programs through partnerships. There will be no further significant investment in these programs. Instead, LPCN 1148’s Phase 2 proof-of-concept study is being completed, and the company is pursuing ex-U.S. commercialization through partnerships of LPCN 1148 and TLANDO.
What will be the next step for LPCN?
Lipocine (LPCN) currently has $37.4 million in cash, cash equivalents, and marketable investments as of June 30, 2022. LPCN believes this cash will last until at least September 30, 2023, as well as support operations.